Animal models of asthma: value, limitations and opportunities for alternative approaches.

Asthma remains an area of considerable unmet medical need. Few new drugs have made it to the clinic during the past 50 years, with many that perform well in preclinical animal models of asthma, failing in humans owing to lack of safety and efficacy. The failure to translate promising drug candidates from animal models to humans has led to questions about the utility of in vivo studies and to demand for more predictive models and tools based on the latest technologies. Following a workshop with experts from academia and the pharmaceutical industry, we suggest here a disease modelling framework designed to better understand human asthma, and accelerate the development of safe and efficacious new asthma drugs that go beyond symptomatic relief.

[1]  N. Pearce,et al.  How much asthma is really attributable to atopy? , 1999, Thorax.

[2]  P. Howarth,et al.  A new look at the pathogenesis of asthma , 2009, Clinical science.

[3]  B. Ma,et al.  Transgenic modeling of interleukin-13 in the lung. , 2003, Chest.

[4]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[5]  J. Bousquet,et al.  Epidemiologic study of the genetics and environment of asthma, bronchial hyperresponsiveness, and atopy. , 2002, Chest.

[6]  S. Shapiro,et al.  Animal models of asthma: Pro: Allergic avoidance of animal (model[s]) is not an option. , 2006, American journal of respiratory and critical care medicine.

[7]  Martyn R Partridge,et al.  Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. , 2010, The Journal of allergy and clinical immunology.

[8]  W. Cookson.  The immunogenetics of asthma and eczema: a new focus on the epithelium , 2004, Nature Reviews Immunology.

[9]  E. Israel,et al.  Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. , 2010, The Journal of allergy and clinical immunology.

[10]  I. Pavord,et al.  Mepolizumab in refractory eosinophilic asthma , 2010, Thorax.

[11]  A. Kisselgof,et al.  Genetic variability in pulmonary physiological, cellular, and antibody responses to antigen in mice. , 1999, American journal of respiratory and critical care medicine.

[12]  M. Epstein.  Are mouse models of allergic asthma useful for testing novel therapeutics? , 2006, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[13]  I. Kola,et al.  The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.

[14]  N. Pearce,et al.  Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? , 1999, The Journal of allergy and clinical immunology.

[15]  W. Busse,et al.  Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. , 2001, The Journal of allergy and clinical immunology.

[16]  Patricia M. LoRusso,et al.  Phase 0 clinical trials: an answer to drug development stagnation? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Ulrich Mohr,et al.  Experimental approaches to evaluate respiratory allergy in animal models. , 2005, Experimental and Toxicological Pathology.

[18]  D. Spina,et al.  Role of cytokines and chemokines in bronchial hyperresponsiveness and airway inflammation. , 2002, Pharmacology & therapeutics.

[19]  N. Künzli,et al.  Anti-Interleukin-5 Therapy and Severe Asthma , 2009 .

[20]  H. Paramesh.  Epidemiology of asthma in India , 2002, Indian journal of pediatrics.

[21]  L. Janssen,et al.  Effects of allergen on airway narrowing dynamics as assessed by lung-slice technique , 2008, European Respiratory Journal.

[22]  D. Malone,et al.  Evaluation of Risk Factors and Health Outcomes among Persons with Asthma , 2009, The Journal of asthma : official journal of the Association for the Care of Asthma.

[23]  F. Martinez.  Safety of long-acting beta-agonists--an urgent need to clear the air. , 2005, The New England journal of medicine.

[24]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[25]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[26]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[27]  I. Pavord,et al.  Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. , 2004, The Journal of allergy and clinical immunology.

[28]  P. O'Byrne,et al.  Provoked models of asthma: what have we learnt? , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  F. Sundler,et al.  The mouse trap. , 1997, Trends in pharmacological sciences.

[30]  W. Sibbald.  An alternative pathway for preclinical research in fluid management , 2000, Critical care.

[31]  H. Magnussen,et al.  The early allergic response in small airways of human precision-cut lung slices , 2003, European Respiratory Journal.

[32]  R. Homer,et al.  Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling. , 2006, Proceedings of the American Thoracic Society.

[33]  J. Willmann,et al.  Molecular imaging in drug development , 2008, Nature Reviews Drug Discovery.

[34]  J. Lavoie,et al.  Heaves, an asthma-like equine disease, involves airway smooth muscle remodeling. , 2006, The Journal of allergy and clinical immunology.

[35]  C. Reinero.  Advances in the understanding of pathogenesis, and diagnostics and therapeutics for feline allergic asthma. , 2011, Veterinary journal.

[36]  C. Persson.  Con: mice are not a good model of human airway disease. , 2002, American journal of respiratory and critical care medicine.

[37]  David Roblin,et al.  Translational research in the pharmaceutical industry: from bench to bedside. , 2006, Drug discovery today.

[38]  M. Yarmush,et al.  Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. , 2009, Biochemical pharmacology.

[39]  M. Kojima,et al.  Mouse model of airway remodeling: strain differences. , 2003, American journal of respiratory and critical care medicine.

[40]  Song Huang,et al.  In vitro organ culture models of asthma , 2009 .

[41]  Yu-zhi Chen.  [Comparative analysis of the state of asthma prevalence in children from two nation-wide surveys in 1990 and 2000 year]. , 2004, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[42]  Z. Hantos,et al.  Measuring lung function in murine models of pulmonary disease , 2004 .

[43]  Ali Khademhosseini,et al.  Microfluidics for drug discovery and development: from target selection to product lifecycle management. , 2008, Drug discovery today.

[44]  C. Venema,et al.  Feline Asthma: What's New and where might Clinical Practice be Heading? , 2010, Journal of feline medicine and surgery.

[45]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[46]  Rakesh K. Kumar,et al.  The "classical" ovalbumin challenge model of asthma in mice. , 2008, Current drug targets.

[47]  Shuichi Takayama,et al.  Microfluidic Endothelium for Studying the Intravascular Adhesion of Metastatic Breast Cancer Cells , 2009, PloS one.

[48]  Animal models of asthma and chronic obstructive pulmonary disease. , 2008, Pulmonary pharmacology & therapeutics.

[49]  L. Borish.  IL-4 and IL-13 dual antagonism: a promising approach to the dilemma of generating effective asthma biotherapeutics. , 2010, American journal of respiratory and critical care medicine.

[50]  A. Woodcock,et al.  Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. , 2007, American journal of respiratory and critical care medicine.

[51]  N. Pearce,et al.  β agonists: What is the evidence that their use increases the risk of asthma morbidity and mortality? , 1999 .

[52]  E. R. Mcfadden,et al.  A century of asthma. , 2004, American journal of respiratory and critical care medicine.

[53]  I. Pavord,et al.  Interleukin‐4 and ‐13 expression is co‐localized to mast cells within the airway smooth muscle in asthma , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[54]  Wayne Mitzner,et al.  Invasive and noninvasive methods for studying pulmonary function in mice , 2007, Respiratory research.

[55]  P. Foster,et al.  New insights into the generation of Th2 immunity and potential therapeutic targets for the treatment of asthma , 2011, Current opinion in allergy and clinical immunology.

[56]  S. Holgate,et al.  The Roles of Cells and Mediators in a Computer Model of Chronic Asthma , 2001, International Archives of Allergy and Immunology.

[57]  S. Holgate,et al.  Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. , 2007, Respiratory medicine.

[58]  Matthew H. M. Lim,et al.  Perfused multiwell plate for 3D liver tissue engineering. , 2010, Lab on a chip.

[59]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[60]  L. Ellis,et al.  Finding the tumor copycat: Therapy fails, patients don't , 2010, Nature Medicine.

[61]  M. Epstein.  Modeling allergic asthma: from in vitro assays to virtual patients , 2004 .

[62]  Bong Geun Chung,et al.  Microfluidic synthesis of pure chitosan microfibers for bio-artificial liver chip. , 2010, Lab on a chip.

[63]  K. Marquette,et al.  Efficacy of IL-13 neutralization in a sheep model of experimental asthma. , 2007, American journal of respiratory cell and molecular biology.

[64]  D. van Velzen,et al.  Kinetics and quantitation of eosinophil and neutrophil recruitment to allergic lung inflammation in a brown Norway rat model. , 1997, American journal of respiratory cell and molecular biology.

[65]  P. Sandercock,et al.  Comparison of treatment effects between animal experiments and clinical trials: systematic review , 2006, BMJ : British Medical Journal.

[66]  James G. Martin,et al.  Airway smooth muscle growth from the perspective of animal models , 2003, Respiratory Physiology & Neurobiology.

[67]  Stephen T Holgate,et al.  Role of deficient type III interferon-λ production in asthma exacerbations , 2006, Nature Medicine.

[68]  C. Oh,et al.  Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma , 2010, European Respiratory Review.

[69]  B. Rogala,et al.  Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. , 2008, Recent patents on inflammation & allergy drug discovery.

[70]  G. Spadaro,et al.  The anti‐IgE/anti‐FcεRIα autoantibody network in allergic and autoimmune diseases , 1999 .

[71]  T J Maguire,et al.  Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. , 2009, Current drug metabolism.

[72]  E. Vollmer,et al.  Characterisation of guinea pig precision-cut lung slices: comparison with human tissues , 2006, European Respiratory Journal.

[73]  T. Colby,et al.  Coexpression of IL-5 and Eotaxin-2 in Mice Creates an Eosinophil-Dependent Model of Respiratory Inflammation with Characteristics of Severe Asthma1 , 2007, The Journal of Immunology.

[74]  R. Panettieri,et al.  Regulation of inflammation by airway smooth muscle , 2008, Current allergy and asthma reports.

[75]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[76]  S. Holgate,et al.  Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. , 2005, The Journal of allergy and clinical immunology.

[77]  P. Vanderslice,et al.  Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. , 2008, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[78]  A. Custovic,et al.  What are we learning from genetic cohort studies? , 2006, Paediatric respiratory reviews.

[79]  I. Pavord,et al.  Increased sputum and bronchial biopsy IL-13 expression in severe asthma. , 2008, The Journal of allergy and clinical immunology.

[80]  P. Howarth,et al.  Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis. , 2002, American journal of respiratory cell and molecular biology.

[81]  Joan E Nichols,et al.  Engineering of a complex organ: progress toward development of a tissue-engineered lung. , 2008, Proceedings of the American Thoracic Society.

[82]  Ian M Adcock,et al.  New targets for drug development in asthma , 2008, The Lancet.

[83]  M. Holtzman.  Drug development for asthma. , 2003, American journal of respiratory cell and molecular biology.

[84]  J. Barberà,et al.  Gas exchange response to a PAF receptor antagonist, SR 27417A, in acute asthma: a pilot study. , 1999, The European respiratory journal.

[85]  K. Suh,et al.  A multi-layer microfluidic device for efficient culture and analysis of renal tubular cells. , 2010, Lab on a chip.

[86]  J. Bousquet,et al.  [Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy (EGEA) - First results of a multi-disciplinary study]. , 2002, Revue des maladies respiratoires.

[87]  I. Cuthill,et al.  Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research † , 2012, Osteoarthritis and cartilage.

[88]  S. Holgate.  A look at the pathogenesis of asthma: the need for a change in direction. , 2010, Discovery medicine.

[89]  J. Metcalf,et al.  Adenovirus Type 7 Induces Interleukin-8 in a Lung Slice Model and Requires Activation of Erk , 2004, Journal of Virology.

[90]  Mark R. Trusheim,et al.  Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.

[91]  J. Westwick,et al.  Therapeutic Effect of IL-13 Immunoneutralization During Chronic Experimental Fungal Asthma1 , 2001, The Journal of Immunology.

[92]  J. Bates,et al.  Measuring the lung function in the mouse: the challenge of size , 2003, Respiratory research.

[93]  William Shain,et al.  An endothelial and astrocyte co-culture model of the blood-brain barrier utilizing an ultra-thin, nanofabricated silicon nitride membrane. , 2005, Lab on a chip.

[94]  Charles Auffray,et al.  An integrative systems biology approach to understanding pulmonary diseases. , 2010, Chest.

[95]  Innovation OR Stagnation.  Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[96]  M. Moss.  Asthmatic Bronchial Epithelial Cells Have a Deficient Innate Immune Response to Infection With Rhinovirus , 2006, Pediatrics.

[97]  J. Bates,et al.  Penh is not a measure of airway resistance! , 2007, European Respiratory Journal.

[98]  G. Anderson,et al.  Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease , 2008, The Lancet.

[99]  Jiri Aubrecht,et al.  Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact , 2010, Nature Reviews Drug Discovery.

[100]  Shuichi Takayama,et al.  Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in microfluidic airway systems , 2007, Proceedings of the National Academy of Sciences.

[101]  D. Corry,et al.  Promise and pitfalls in animal-based asthma research , 2006, Immunologic research.

[102]  P. Howarth,et al.  Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms , 2007, European Respiratory Journal.

[103]  Albert Folch,et al.  Local induction of acetylcholine receptor clustering in myotube cultures using microfluidic application of agrin. , 2006, Biophysical journal.

[104]  T. To,et al.  Prioritised research agenda for prevention and control of chronic respiratory diseases , 2010, European Respiratory Journal.

[105]  J. Bates,et al.  A reevaluation of the validity of unrestrained plethysmography in mice. , 2002, Journal of applied physiology.

[106]  B. Canning.  Modeling asthma and COPD in animals: a pointless exercise? , 2003, Current opinion in pharmacology.

[107]  F. Cassee,et al.  Fine Ambient Particles from Various Sites in Europe Exerted a Greater IgE Adjuvant Effect than Coarse Ambient Particles in a Mouse Model , 2008, Journal of toxicology and environmental health. Part A.

[108]  M. Sanderson,et al.  Mechanisms of airway smooth muscle relaxation induced by beta2-adrenergic agonists. , 2010, Frontiers in bioscience.

[109]  S. Shapiro,et al.  The use of transgenic mice for modeling airways disease. , 2008, Pulmonary pharmacology & therapeutics.

[110]  K. Rabe,et al.  Safety of long-acting β-agonists: urgent need to clear the air remains , 2009, European Respiratory Journal.

[111]  D. Postma,et al.  Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. , 2003, American journal of respiratory and critical care medicine.

[112]  G. FitzGerald.  Anticipating change in drug development: the emerging era of translational medicine and therapeutics , 2005, Nature Reviews Drug Discovery.

[113]  Sally E Wenzel,et al.  A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. , 2010, American journal of respiratory and critical care medicine.

[114]  D. English,et al.  Asthma, Asthma Medications, and Prostate Cancer Risk , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[115]  Jason H T Bates,et al.  Measuring lung function in mice: the phenotyping uncertainty principle. , 2003, Journal of applied physiology.

[116]  A. Wanner.  clinical implications of basic research Utility of Animal Models in the Study of Human Airway Disease , 2022 .

[117]  C J Musante,et al.  Small- and large-scale biosimulation applied to drug discovery and development. , 2002, Drug discovery today.

[118]  P. Cooper,et al.  Airway mechanics and methods used to visualize smooth muscle dynamics in vitro. , 2009, Pulmonary pharmacology & therapeutics.

[119]  Hywel Morgan,et al.  On-chip epithelial barrier function assays using electrical impedance spectroscopy. , 2010, Lab on a chip.

[120]  M. Holtzman,et al.  A centennial history of research on asthma pathogenesis. , 2005, American journal of respiratory cell and molecular biology.

[121]  D. Strachan,et al.  Exercise-Induced Bronchospasm and Atopy in Ghana: Two Surveys Ten Years Apart , 2007, PLoS medicine.

[122]  C. Lloyd.  Building better mouse models of asthma , 2007, Current allergy and asthma reports.

[123]  M. J. Saad,et al.  Obesity enhances eosinophilic inflammation in a murine model of allergic asthma , 2010, British journal of pharmacology.

[124]  R. Homer,et al.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. , 1999, The Journal of clinical investigation.

[125]  Albert Folch,et al.  Differentiation-on-a-chip: a microfluidic platform for long-term cell culture studies. , 2005, Lab on a chip.

[126]  D. Fabian,et al.  The global burden of asthma: executive summary of the GINA Dissemination Committee Report , 2004, Allergy.

[127]  J. Sheikh,et al.  Current strategies in the management of hypereosinophilic syndrome, including mepolizumab , 2010, Current medical research and opinion.

[128]  S. Holgate.  Asthma: more than an inflammatory disease. , 2002, Current opinion in allergy and clinical immunology.

[129]  K. Rabe,et al.  Animal models for human asthma: the perspective of a clinician. , 2008, Current drug targets.

[130]  R D Combes,et al.  Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[131]  Bruce H. Littman,et al.  The ultimate model organism: progress in experimental medicine , 2005, Nature Reviews Drug Discovery.

[132]  K. Pinkerton,et al.  Asthma: a comparison of animal models using stereological methods , 2006, European Respiratory Review.

[133]  D. Ingber,et al.  Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.

[134]  M. Yamakido,et al.  Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. , 1995, American journal of respiratory and critical care medicine.

[135]  R. Panettieri,et al.  Is airway smooth muscle the "missing link" modulating airway inflammation in asthma? , 2008, Chest.

[136]  Deborah A Meyers,et al.  Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. , 2010, The Journal of allergy and clinical immunology.

[137]  S. Weiss,et al.  Association of control and risk of severe asthma‐related events in severe or difficult‐to‐treat asthma patients , 2007, Allergy.

[138]  M. Wills-Karp,et al.  Interleukin‐13 in asthma pathogenesis , 2004, Immunological reviews.

[139]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.

[140]  P. Sly,et al.  Animal models of asthma , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[141]  R. Pabst.  Animal Models for Asthma: Controversial Aspects and Unsolved Problems , 2003, Pathobiology.

[142]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[143]  S. Willsie.  Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia , 2010 .

[144]  R. A. Killington,et al.  Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation , 2008, Nature Medicine.

[145]  Florence Demenais,et al.  A large-scale, consortium-based genomewide association study of asthma. , 2010, The New England journal of medicine.

[146]  P. Paré,et al.  The use and misuse of Penh in animal models of lung disease. , 2004, American journal of respiratory cell and molecular biology.

[147]  T. Lancet.  Asthma: still more questions than answers , 2008, The Lancet.

[148]  A. Bree,et al.  IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. , 2007, The Journal of allergy and clinical immunology.

[149]  A. Nials,et al.  Mouse models of allergic asthma: acute and chronic allergen challenge , 2008, Disease Models & Mechanisms.

[150]  Allergies During.  A Randomized, Controlled Phase 2 Study of AMG 317, an IL-4Ralpha Antagonist, in Patients With Asthma , 2010 .

[151]  E. Gelfand.  Pro: mice are a good model of human airway disease. , 2002, American journal of respiratory and critical care medicine.

[152]  J. Bousquet,et al.  EGEA (Epidemiological study on the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy)-- descriptive characteristics. , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[153]  Michael L Shuler,et al.  A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers , 2009, Biotechnology and bioengineering.

[154]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[155]  S. Holgate.  Epithelium dysfunction in asthma. , 2007, The Journal of allergy and clinical immunology.

[156]  S. Johnston,et al.  Role of deficient type III interferon-lambda production in asthma exacerbations. , 2006, Nature medicine.

[157]  S. Holgate,et al.  The mouse trap: It still yields few answers in asthma. , 2006, American journal of respiratory and critical care medicine.

[158]  T. Mahr.  Wheezing Rhinovirus Illnesses in Early Life Predict Asthma Development in High-Risk Children , 2009, Pediatrics.